Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event
28 Jun 2019Immunicum AB (publ) Announces Positive Topline Results from the Phase I/II Clinical Trial in GIST
12 Jun 2019Immunicum AB (publ) Announces Outcome of Subscription in Employee Incentive Program 2019/2022
28 May 2019
Latest Corporate presentation
Corporate presentation August 2019News
-
Cell & Gene Therapy Insights 2019 – Abstract
9 Jul 2019 -
Edison Report from 27 June 2019
1 Jul 2019 -
Immunicum utvecklar banbrytande cancerstrategi – Radiumhemmets Forskningsfonder Article
29 May 2019 -
RedEye Pre-ASCO Seminar – Corporate Presentation Video
29 May 2019 -
Immunicums ilixadencel ger nytt hopp till cancerpatienter – BioStock Article
29 Apr 2019
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
